<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Crystal-induced acute kidney injury</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Crystal-induced acute kidney injury</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Crystal-induced acute kidney injury</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark A Perazella, MD, FACP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul M Palevsky, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric N Taylor, MD, MSc, FASN</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 31, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H4164196"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Crystal-induced acute kidney injury (AKI) is caused by the intratubular precipitation of crystals, which results in obstruction. Crystal-induced AKI most commonly occurs as a result of acute uric acid nephropathy and following the administration of drugs or toxins that are poorly soluble or have metabolites that are poorly soluble in urine [<a href="#rid1">1,2</a>]. Other drugs or medications may be metabolized to insoluble products such as oxalate (ethylene glycol, <a class="drug drug_general" data-topicid="9776" href="/d/drug information/9776.html" rel="external">vitamin C</a>), which are associated with precipitation of calcium oxalate crystals within tubular lumens and kidney injury.</p><p>This topic review discusses drug-related crystal-induced AKI. Uric acid nephropathy and acute phosphate nephropathy are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/7379.html" rel="external">"Uric acid kidney diseases"</a> and  <a class="medical medical_review" href="/d/html/7218.html" rel="external">"Acute phosphate nephropathy"</a>.)</p><p class="headingAnchor" id="H4164203"><span class="h1">ETIOLOGY</span><span class="headingEndMark"> — </span>Multiple drugs and toxins cause intratubular crystal-induced obstruction and tubulointerstitial injury. Common agents include:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">Acyclovir</a></p><p class="bulletIndent1"><span class="glyph">●</span>Sulfonamide antibiotics</p><p class="bulletIndent1"><span class="glyph">●</span>Ethylene glycol</p><p class="bulletIndent1"><span class="glyph">●</span>Megadose <a class="drug drug_general" data-topicid="9776" href="/d/drug information/9776.html" rel="external">vitamin C</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">Methotrexate</a></p><p class="bulletIndent1"><span class="glyph">●</span>Protease inhibitors</p><p></p><p>Other agents that have been described in case reports to cause crystal-induced acute kidney injury (AKI) include <a class="drug drug_general" data-topicid="10179" href="/d/drug information/10179.html" rel="external">orlistat</a>, oral <a class="drug drug_general" data-topicid="10269" href="/d/drug information/10269.html" rel="external">sodium phosphate</a> purgatives, <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a>, <a class="drug drug_general" data-topicid="10016" href="/d/drug information/10016.html" rel="external">triamterene</a>, and high-dose <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a> [<a href="#rid1">1,3</a>].</p><p class="headingAnchor" id="H4164210"><span class="h1">CLINICAL PRESENTATION AND DIAGNOSIS</span><span class="headingEndMark"> — </span>Patients with drug-related crystal-induced acute kidney injury (AKI) are usually asymptomatic, and kidney injury is detected by an increased serum creatinine [<a href="#rid4">4</a>]. Occasionally, patients present within one to seven days after initiation of the offending drug with renal colic symptoms such as flank or abdominal pain, nausea, or vomiting.</p><p>Urinalysis often reveals hematuria, pyuria, and crystalluria [<a href="#rid1">1,5</a>]. Significant proteinuria (ie, &gt;500 mg/day) is not commonly observed, unless the patient has underlying proteinuric kidney disease and subsequently develops crystal-induced AKI.</p><p>The diagnosis is suggested by the appearance of crystals in the urine, the morphology of which depends upon the specific causative drug (see <a class="local">'Specific agents'</a> below). Urinary casts containing crystals generally reflect crystal-related kidney injury. However, crystalluria may also be observed in patients who have no evidence of AKI [<a href="#rid5">5</a>].</p><p>Definitive diagnosis is obtained by examination of histology obtained by kidney biopsy. In general, however, a biopsy is not indicated in patients who present with AKI in the setting of starting a drug that is known to cause crystal-induced AKI, unless atypical features (such as significant proteinuria in a patient who does not have underlying proteinuric kidney disease) are present.</p><p>The differential diagnosis for crystal-induced AKI is AKI from any cause and, among patients who present with hematuria and even modest proteinuria, glomerulonephritis. The diagnostic approaches to these disorders are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/7188.html" rel="external">"Diagnostic approach to adult patients with subacute kidney injury in an outpatient setting"</a> and  <a class="medical medical_review" href="/d/html/3041.html" rel="external">"Glomerular disease: Evaluation and differential diagnosis in adults"</a>.)</p><p>Crystal-induced AKI is generally reversed following discontinuation of the drug, although temporary dialysis may be necessary in some cases, and chronic kidney disease (CKD) may be a long-term consequence of crystal-induced AKI [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H4164217"><span class="h1">RISK FACTORS</span><span class="headingEndMark"> — </span>Risk factors for crystal-induced kidney injury include true and "effective" intravascular volume depletion, underlying kidney or liver disease, and metabolic perturbations that change urinary pH [<a href="#rid1">1,2,6</a>]. The effect of urine pH on crystal formation varies depending upon the specific causative agents. As an example, whereas sulfonamides tend to form crystals in acidic urine, protease inhibitors such as <a class="drug drug_general" data-topicid="9353" href="/d/drug information/9353.html" rel="external">atazanavir</a> form crystals in alkaline urine.</p><p>Excessive drug dosing for a given glomerular filtration rate (GFR) may contribute to the risk of kidney injury [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H101517554"><span class="h1">OVERVIEW OF TREATMENT</span><span class="headingEndMark"> — </span>The correction of volume depletion is critical to prevent crystal-induced acute kidney injury (AKI) among patients at risk. Therapy of established crystal-induced AKI is supportive and consists of volume repletion, usually with isotonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a>, and administration of a loop diuretic in an attempt to wash out the obstructing crystals. The use of loop diuretics is of theoretical benefit only, and its efficacy has not been shown. Despite the absence of proven efficacy, we generally administer <a class="drug drug_general" data-topicid="8482" href="/d/drug information/8482.html" rel="external">furosemide</a>. Fluid loss induced by the diuretic must be replaced to prevent volume depletion and a late slowing of flow within the tubules.</p><p>In addition to volume repletion and loop diuretics, among patients with crystal-induced AKI due to specific medications (as, for example, sulfonamide antibiotics and <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>), adjusting the urine pH to achieve better solubility of the crystal may be of benefit. These issues and specific treatments, where indicated, are discussed below. (See <a class="local">'Sulfonamide antibiotics'</a> below and <a class="local">'Methotrexate'</a> below.)</p><p class="headingAnchor" id="H4164281"><span class="h1">SPECIFIC AGENTS</span></p><p class="headingAnchor" id="H101518418"><span class="h2">Acyclovir</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">Acyclovir</a> is rapidly excreted in the urine (being both filtered and secreted) and has a relatively low solubility [<a href="#rid5">5</a>]. Thus, bolus intravenous (IV) therapy, especially if the patient is volume depleted, may lead to the deposition of acyclovir crystals in the tubules, resulting in intratubular obstruction and foci of interstitial inflammation [<a href="#rid4">4,5</a>]. <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">Ganciclovir</a>, another antiviral agent that is structurally related to acyclovir and is also excreted in the urine, appears to be associated with a much lower risk of crystal-induced acute kidney injury (AKI) compared with acyclovir [<a href="#rid5">5,7</a>]. In addition, oral <a class="drug drug_general" data-topicid="10034" href="/d/drug information/10034.html" rel="external">valacyclovir</a> may rarely precipitate AKI and crystalluria if an overdose is taken, or when given to patients with other risk factors for AKI (eg, chronic kidney disease (CKD), hypovolemia, nonsteroidal antiinflammatory drug use) [<a href="#rid8">8,9</a>].</p><p>Kidney function in affected patients typically begins to deteriorate within 24 to 48 hours after therapy with <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a> is initiated [<a href="#rid1">1,6</a>].<strong> </strong>Patients may complain of nausea and flank or abdominal pain at this time, presumably induced by the urinary tract obstruction [<a href="#rid5">5</a>]. In some cases, birefringent, needle-shaped acyclovir crystals, occasionally engulfed by white cells, can be seen in the urine, particularly under polarized light  (<a class="graphic graphic_diagnosticimage graphicRef114167" href="/d/graphic/114167.html" rel="external">image 1</a>).</p><p>The decline in kidney function is usually mild but occasionally may be severe, with marked increases in the plasma creatinine concentration in some cases [<a href="#rid10">10,11</a>]. However, complete recovery typically occurs within four to nine days after <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a> is discontinued.</p><p>It is likely that most cases of <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a> nephrotoxicity, which is likely due in part to direct tubular toxicity and tubulointerstitial inflammation and in part to luminal crystal-associated obstruction, can be prevented by prior volume repletion (with the urine output maintained above 75 mL/hour) and slow IV drug infusion over one to two hours. We generally administer IV isotonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> at a rate of 125 mL/hour, starting at least one hour prior to the administration of acyclovir and continuing for six hours after the acyclovir infusion is finished. Patients who develop AKI can usually be safely rechallenged (if necessary) by limiting the dose to ≤250 mg/m<sup>2</sup> [<a href="#rid5">5</a>]. Oral therapy is usually well tolerated, presumably due to a less rapid rate of acyclovir excretion. Rarely, AKI can develop with oral acyclovir in patients with underlying kidney disease (and excessive dosing) and severe volume depletion [<a href="#rid12">12,13</a>].</p><p>Therapy of established kidney failure is supportive and consists of volume repletion, usually with isotonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> and administration of a loop diuretic in an attempt to wash out the obstructing crystals. As noted above, although the use of loop diuretics is of theoretical benefit only and its efficacy has not been shown, we generally administer <a class="drug drug_general" data-topicid="8482" href="/d/drug information/8482.html" rel="external">furosemide</a>. Fluid loss induced by the diuretic must be replaced to prevent volume depletion and a late slowing of flow within the tubules. (See  <a class="medical medical_review" href="/d/html/2296.html" rel="external">"Maintenance and replacement fluid therapy in adults"</a>.)</p><p>Although hemodialysis may remove substantial amounts of <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a> [<a href="#rid10">10</a>], it has not been shown to reverse or limit the duration of acyclovir-induced AKI and is not indicated for this purpose. However, neurotoxicity may develop in patients who develop severe acyclovir-induced AKI [<a href="#rid13">13-15</a>], and, in this setting, hemodialysis may be indicated in order to remove the drug [<a href="#rid10">10</a>].</p><p>In addition, hemodialysis may be required to correct the metabolic sequelae of AKI. (See  <a class="medical medical_review" href="/d/html/1927.html" rel="external">"Kidney replacement therapy (dialysis) in acute kidney injury in adults: Indications, timing, and dialysis dose"</a>.)</p><p class="headingAnchor" id="H4164288"><span class="h2">Sulfonamide antibiotics</span><span class="headingEndMark"> — </span>Some sulfonamide antibiotics are relatively insoluble in acid urine, particularly <a class="drug drug_general" data-topicid="9960" href="/d/drug information/9960.html" rel="external">sulfadiazine</a> and sulfamethoxazole, which are used in high doses to treat toxoplasmosis and <em>Pneumocystis jirovecii</em> infection in immunocompromised patients [<a href="#rid5">5,16-18</a>]. Up to 29 percent of patients treated with sulfadiazine are at risk to develop AKI [<a href="#rid1">1,16-19</a>] because this drug is highly insoluble in urine with a pH of ≤5.5 [<a href="#rid19">19</a>]. Intrarenal sulfadiazine precipitation may also result in nephrolithiasis [<a href="#rid18">18</a>].</p><p>The risk of crystal precipitation increases with doses of <a class="drug drug_general" data-topicid="9960" href="/d/drug information/9960.html" rel="external">sulfadiazine</a> of 4 to 6 g/day and of sulfamethoxazole of 50 to 100 mg/kg/day [<a href="#rid16">16-19</a>]. Alkalinization of the urine to a pH &gt;7.15 increases sulfadiazine solubility more than 20-fold [<a href="#rid5">5,16</a>].</p><p>Sulfonamide crystals can assume many shapes, in part dependent upon the specific sulfonamide present. The most common morphology includes needle-shaped crystals, rosettes, and those resembling shocks or sheaves of wheat  (<a class="graphic graphic_picture graphicRef56708" href="/d/graphic/56708.html" rel="external">picture 1</a>). <a class="drug drug_general" data-topicid="9960" href="/d/drug information/9960.html" rel="external">Sulfadiazine</a> sludge or small calculi in the calyces can also be detected in some cases as bilateral, layered clusters of echogenic material on kidney ultrasonography [<a href="#rid5">5,19</a>].</p><p>Intrarenal <a class="drug drug_general" data-topicid="9960" href="/d/drug information/9960.html" rel="external">sulfadiazine</a> precipitation may be prevented by maintaining fluid intake above 3 L/day, which may be administered orally or intravenously [<a href="#rid18">18</a>]. Patients who are receiving sulfadiazine should be monitored by serial urinalyses for the development of crystalluria. Among patients who develop crystalluria, we administer an IV bicarbonate solution to alkalinize the urine to ≥7.15 in order to prevent AKI. To patients who are euvolemic and have normal kidney function and a normal serum sodium concentration, we give a solution containing 75 mEq <a class="drug drug_general" data-topicid="9928" href="/d/drug information/9928.html" rel="external">sodium bicarbonate</a> per liter of sterile water. If the patient is hypovolemic, we give an isotonic solution (containing 75 mEq sodium bicarbonate per liter of one-half isotonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a>). We generally give approximately 3 L/day (ie, infusion rate of 125 mL/hour).</p><p>Patients who are receiving prophylactic IV bicarbonate should be closely monitored by physical exam for volume overload and by daily measurement of serum creatinine and electrolytes for development of AKI, alkalosis, or other electrolyte abnormalities.</p><p>Some patients may develop AKI despite prophylactic volume repletion and alkalinization of urine. Among such patients, AKI usually resolves when the sulfonamide is discontinued. The treatment of established AKI is supportive. Volume depletion, if present, should be treated in all patients, usually with isotonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a>. The administration of loop diuretics may assist recovery of kidney function by clearing obstructive casts from tubular lumen, although there are no published data that have demonstrated a benefit of loop diuretics.</p><p>Among patients with established AKI, a forced alkaline diuresis to a target urine pH &gt;7.15 may provide benefit by increasing the solubility of <a class="drug drug_general" data-topicid="9960" href="/d/drug information/9960.html" rel="external">sulfadiazine</a>, although there are no published studies that show that this treatment reverses or limits the duration of established sulfonamide-associated AKI.</p><p>In addition to a lack of clear evidence of benefit, maintaining the urine pH &gt;7.15 is difficult in patients with established AKI. There are also potential risks to alkalinization of the plasma, such as promoting calcium phosphate deposition (which is more likely if hyperphosphatemia is present) and inducing or worsening the manifestations of hypocalcemia by both a direct membrane effect and a reduction in ionized calcium levels [<a href="#rid20">20</a>]. Manifestations of severe hypocalcemia include tetany, seizures, and cardiac arrhythmias. (See  <a class="medical medical_review" href="/d/html/833.html" rel="external">"Clinical manifestations of hypocalcemia"</a>.)</p><p>Despite these limitations, patients who are appropriately monitored may benefit from IV bicarbonate therapy. For patients who have a urine pH ≤7.15, we generally administer a solution (mixed by the pharmacy) containing 140 mEq of <a class="drug drug_general" data-topicid="9928" href="/d/drug information/9928.html" rel="external">sodium bicarbonate</a> per liter of sterile water at a rate of 125 mL/hour along with a loop diuretic such as <a class="drug drug_general" data-topicid="8482" href="/d/drug information/8482.html" rel="external">furosemide</a>, providing patients are not oliguric and do not have hypocalcemia, metabolic alkalosis, or an indication for acute hemodialysis. (See  <a class="medical medical_review" href="/d/html/1927.html" rel="external">"Kidney replacement therapy (dialysis) in acute kidney injury in adults: Indications, timing, and dialysis dose", section on 'Urgent indications'</a>.)</p><p>Among patients with established AKI, the bicarbonate infusion should be discontinued if the urine pH does not rise above 7 after 12 hours or if metabolic alkalosis or volume overload develops.</p><p>There is no benefit to hemodialysis for the removal of sulfonamides.</p><p class="headingAnchor" id="H4164341"><span class="h2">Methotrexate</span><span class="headingEndMark"> — </span>Approximately 90 percent of administered <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> is normally excreted unchanged in the urine. High-dose IV methotrexate can both precipitate in the tubules and cause direct tubular injury  (<a class="graphic graphic_diagnosticimage graphicRef114168" href="/d/graphic/114168.html" rel="external">image 2</a>) [<a href="#rid21">21-23</a>].<strong> </strong>The risk of methotrexate-induced nephrotoxicity is increased with an acidic urine (since methotrexate is poorly soluble in an acidic urine) and with volume depletion (which decreases urine flow rate and increases the concentration of methotrexate in tubular fluid). In addition, the risk of methotrexate nephrotoxicity is higher when there is sustained elevation in the plasma methotrexate concentration [<a href="#rid24">24</a>].</p><p>The risk of developing AKI can be minimized by prior volume repletion (both to maintain a high urine flow and to lower the concentration of <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> in the tubular fluid) and by alkalinization of the urine to a pH &gt;7, which can increase the solubility of methotrexate by as much as 10-fold [<a href="#rid22">22</a>]. Among all patients who are receiving IV methotrexate, we administer an IV bicarbonate solution to alkalinize the urine to ≥7 in order to prevent AKI. To patients who are euvolemic and have normal kidney function and a normal serum sodium concentration, we give a solution containing 75 mEq <a class="drug drug_general" data-topicid="9928" href="/d/drug information/9928.html" rel="external">sodium bicarbonate</a> per liter of sterile water that is mixed by the pharmacy. If the patient is hypovolemic, we give an isotonic solution (containing 75 mEq sodium bicarbonate per liter of one-half isotonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a>). We generally give approximately 3 L/day (ie, infusion rate of 125 mL/hour). The bicarbonate infusion should be begun 12 hours before methotrexate administration and continued for 24 to 48 hours.</p><p>The incidence of methotrexate-induced AKI in the era of routine intravascular volume repletion and urinary alkalinization was 1.8 percent in an analysis of data from clinical trials in osteosarcoma [<a href="#rid25">25</a>]. However, the incidence of AKI may be 10 percent or higher in patients with risk factors for AKI, such as a CKD [<a href="#rid26">26,27</a>]. </p><p>Methotrexate-induced AKI is typically nonoliguric and usually reversible [<a href="#rid23">23,24</a>]. The plasma creatinine concentration usually peaks within the first week and returns well toward baseline levels within one to three weeks [<a href="#rid23">23</a>].</p><p>Treatment of methotrexate-induced AKI is directed at volume repletion, washing out the crystals within tubular lumens via the administration of a loop diuretic, and alkalinization of urine. There are no studies that have proven a benefit of either loop diuretics or alkalinization of urine, and these measures are of theoretical benefit only.</p><p>As described above, maintaining the urine pH above 7 is difficult in patients with AKI and is associated with potential risks, including calcium phosphate deposition and inducing or worsening the manifestations of hypocalcemia by both a direct membrane effect and a reduction in ionized calcium levels [<a href="#rid20">20</a>]. (See <a class="local">'Sulfonamide antibiotics'</a> above.)</p><p>Despite these limitations, given the potential benefit of bicarbonate therapy, we administer a bicarbonate infusion to all patients who have methotrexate-related AKI, providing they are not oliguric and do not have hypocalcemia, metabolic alkalosis, or an indication for acute hemodialysis. (See  <a class="medical medical_review" href="/d/html/1927.html" rel="external">"Kidney replacement therapy (dialysis) in acute kidney injury in adults: Indications, timing, and dialysis dose", section on 'Urgent indications'</a>.)</p><p>We generally administer a solution containing 140 mEq <a class="drug drug_general" data-topicid="9928" href="/d/drug information/9928.html" rel="external">sodium bicarbonate</a> per liter of sterile water at a rate of 125 mL/hour intravenously, along with a loop diuretic such as <a class="drug drug_general" data-topicid="8482" href="/d/drug information/8482.html" rel="external">furosemide</a>, providing patients are not oliguric and do not have hypocalcemia, metabolic alkalosis, or an indication for acute hemodialysis. (See  <a class="medical medical_review" href="/d/html/1927.html" rel="external">"Kidney replacement therapy (dialysis) in acute kidney injury in adults: Indications, timing, and dialysis dose", section on 'Urgent indications'</a>.)</p><p>The bicarbonate infusion should be discontinued if the urine pH does not rise above 7 after 12 hours or if metabolic alkalosis develops.</p><p>AKI often results in an elevated plasma <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> concentration [<a href="#rid24">24</a>]. This is clinically important since decreased urinary excretion of methotrexate results in elevated plasma drug levels that can last for two to three weeks, thereby increasing the risk of toxicity [<a href="#rid23">23</a>]. <a class="drug drug_general" data-topicid="9548" href="/d/drug information/9548.html" rel="external">Leucovorin</a> rescue with or without thymidine is effective in this setting, although higher-than-usual doses of leucovorin are often required based upon the plasma methotrexate concentration [<a href="#rid21">21,23</a>]. Leucovorin should be continued until levels of methotrexate fall below 0.05 micromol/L. (See  <a class="medical medical_review" href="/d/html/1155.html" rel="external">"Therapeutic use and toxicity of high-dose methotrexate", section on 'Prevention and management of high-dose methotrexate toxicity'</a>.)</p><p><a class="drug drug_general" data-topicid="9048" href="/d/drug information/9048.html" rel="external">Glucarpidase</a>, which rapidly metabolizes <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a> and chemically similar antifolates such as <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> to inactive metabolites, may prevent systemic methotrexate toxicity by rapidly lowering serum methotrexate levels that remain unacceptably high despite adequate hydration and urinary alkalinization [<a href="#rid28">28-30</a>]. In one report, for example, 65 patients with CKD<strong> </strong>and an elevated serum methotrexate<strong> </strong>concentration 36 to 42 hours after methotrexate infusion were treated with a single dose of glucarpidase [<a href="#rid30">30</a>]. Fifteen minutes following glucarpidase treatment, serum methotrexate levels decreased by a median of 87 percent.</p><p><a class="drug drug_general" data-topicid="9048" href="/d/drug information/9048.html" rel="external">Glucarpidase</a> also metabolizes <a class="drug drug_general" data-topicid="9548" href="/d/drug information/9548.html" rel="external">leucovorin</a>, which should be continued for two days after glucarpidase administration [<a href="#rid24">24</a>].</p><p><a class="drug drug_general" data-topicid="9048" href="/d/drug information/9048.html" rel="external">Glucarpidase</a> was approved in the US in January 2012 for treatment of toxic <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> plasma concentrations (&gt;1 micromol/L [&gt;1 microm]) in patients with delayed methotrexate clearance due to impaired kidney function [<a href="#rid31">31</a>]. Recommendations for the use of glucarpidase among patients with kidney dysfunction and elevated methotrexate levels are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/1155.html" rel="external">"Therapeutic use and toxicity of high-dose methotrexate", section on 'Glucarpidase (carboxypeptidase G2)'</a>.)</p><p>Drug removal by hemodialysis, charcoal hemoperfusion, or plasma exchange is generally of limited value since <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> is protein bound (approximately 50 percent) and therefore not readily dialyzable, and also has a relatively large extravascular volume of distribution [<a href="#rid21">21,32</a>]. However, in one small case series, daily hemodialysis with high-flux membranes for four to six hours improved methotrexate clearance [<a href="#rid33">33</a>]. In one patient who was dialysis dependent prior to high-dose methotrexate therapy, 63 percent of the drug was cleared in six hours. Analysis of seven separate methotrexate treatments in this patient demonstrated complete drug removal after an average of 5.6 days [<a href="#rid33">33</a>]. In addition, there is significant postdialysis rebound in serum drug levels due to methotrexate's relatively large volume of distribution.</p><p>Limited data also suggest that albumin-based continuous venovenous hemodialysis (CVVHD) may provide better <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> clearance than CVVHD without albumin, presumably due to the effect of better removal of protein-bound methotrexate [<a href="#rid34">34</a>].</p><p class="headingAnchor" id="H4164392"><span class="h2">Protease inhibitors</span></p><p class="headingAnchor" id="H4164424"><span class="h3">Atazanavir</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9353" href="/d/drug information/9353.html" rel="external">Atazanavir</a>, a protease inhibitor used in the treatment of human immunodeficiency virus (HIV) infection, can lead to stone formation and, less commonly, AKI due to its relative insolubility in the urine [<a href="#rid35">35-37</a>].</p><p>The mechanism by which <a class="drug drug_general" data-topicid="9353" href="/d/drug information/9353.html" rel="external">atazanavir</a> causes both nephrolithiasis and AKI is by the precipitation of atazanavir crystals. Atazanavir is much more soluble at lower pH values, especially pH &lt;3 [<a href="#rid38">38</a>]. However, although acidification of urine may increase the solubility of atazanavir, this is difficult to achieve and potentially harmful. Thus, acidification of urine is not recommended.</p><p>An initial case series described 11 patients who developed nephrolithiasis while taking <a class="drug drug_general" data-topicid="9353" href="/d/drug information/9353.html" rel="external">atazanavir</a> [<a href="#rid36">36</a>]. Analysis of the stones demonstrated crystals of atazanavir base, but not metabolites. Eight stones contained a core of atazanavir, while four had a core of calcium oxalate (one patient had two stones).</p><p>Several case reports and 30 cases of atazanavir-associated nephrolithiasis were subsequently reported upon review of the US Food and Drug Administration Adverse Event Reporting System database [<a href="#rid39">39,40</a>]. One study estimated a prevalence of <a class="drug drug_general" data-topicid="9353" href="/d/drug information/9353.html" rel="external">atazanavir</a> stones of 0.97 percent among those taking the drug [<a href="#rid36">36</a>].</p><p>One case of AKI due to atazanavir-associated crystal nephropathy has been reported [<a href="#rid38">38</a>]. In this case, rod-like <a class="drug drug_general" data-topicid="9353" href="/d/drug information/9353.html" rel="external">atazanavir</a> crystals were noted on urine microscopy  (<a class="graphic graphic_picture graphicRef77620" href="/d/graphic/77620.html" rel="external">picture 2</a>), as well as within tubular lumens and kidney interstitium (along with granulomata) on kidney biopsy  (<a class="graphic graphic_picture graphicRef77824" href="/d/graphic/77824.html" rel="external">picture 3</a>).</p><p>Fluid intake of ≥1.5 L/day should be encouraged among patients taking <a class="drug drug_general" data-topicid="9353" href="/d/drug information/9353.html" rel="external">atazanavir</a>.</p><p class="headingAnchor" id="H2107766771"><span class="h3">Other protease inhibitors</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8842" href="/d/drug information/8842.html" rel="external">Darunavir</a> has been associated with crystalluria and crystalline-associated AKI [<a href="#rid41">41</a>], while <a class="drug drug_general" data-topicid="9685" href="/d/drug information/9685.html" rel="external">nelfinavir</a> and <a class="drug drug_general" data-topicid="9877" href="/d/drug information/9877.html" rel="external">saquinavir</a> have been associated with crystalluria and urolithiasis [<a href="#rid42">42</a>].</p><p class="headingAnchor" id="H1208776727"><span class="h2">Oxalate</span><span class="headingEndMark"> — </span>AKI due to oxalate deposition in the kidney has been described in several settings:</p><p class="bulletIndent1"><span class="glyph">●</span>Primary hyperoxaluria (see  <a class="medical medical_review" href="/d/html/6141.html" rel="external">"Primary hyperoxaluria"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ethylene glycol poisoning (see  <a class="medical medical_review" href="/d/html/336.html" rel="external">"Methanol and ethylene glycol poisoning: Pharmacology, clinical manifestations, and diagnosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Secondary hyperoxaluria due to enteric disease (eg, pancreatic insufficiency, inflammatory bowel disease, bowel resection, or gastric bypass) (see  <a class="medical medical_review" href="/d/html/4775.html" rel="external">"Chronic complications of the short bowel syndrome in adults"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>High doses of <a class="drug drug_general" data-topicid="9776" href="/d/drug information/9776.html" rel="external">vitamin C</a> [<a href="#rid43">43,44</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Exposure to hair-straightening products containing glycolic acid [<a href="#rid45">45</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Therapy with the weight loss drug <a class="drug drug_general" data-topicid="10179" href="/d/drug information/10179.html" rel="external">orlistat</a> [<a href="#rid46">46-48</a>] (see  <a class="medical medical_review" href="/d/html/7209.html" rel="external">"Nephrocalcinosis", section on 'Clinical features'</a>)</p><p></p><p>Many patients with oxalate-mediated AKI have preexisting CKD as a risk factor and/or multiple precipitants (eg, volume depletion and enteric hyperoxaluria) [<a href="#rid49">49</a>]. A kidney biopsy case series of 31 patients with oxalate nephropathy (mean serum creatinine of 7.6 mg/dL at presentation) reported the following characteristic risk factors and outcomes [<a href="#rid50">50</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Twenty-four patients (77 percent) had preexisting CKD. The mean baseline serum creatinine in the study was 1.8 mg/dL (estimated glomerular filtration rate [eGFR] 48 mL/min/1.73 m<sup>2</sup>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Eleven patients (36 percent) had an unclear etiology for oxalate nephropathy. Of the 20 remaining patients, the etiology was determined to be multifactorial in 10. Enteric hyperoxaluria was present in 17 patients, and high oxalate intake (from food, tea, or from oxalate precursors such as <a class="drug drug_general" data-topicid="9776" href="/d/drug information/9776.html" rel="external">vitamin C</a>) was identified in 16. Only one patient had primary hyperoxaluria.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Of 26 patients with available follow-up data, 21 patients (81 percent) required dialysis, only one of whom recovered kidney function, and five (19 percent) died within one year.</p><p></p><p class="headingAnchor" id="H4164440"><span class="h2">Oral sodium phosphate purgatives</span><span class="headingEndMark"> — </span>Oral <a class="drug drug_general" data-topicid="10269" href="/d/drug information/10269.html" rel="external">sodium phosphate</a> preparations have been used as laxatives or purgatives for bowel cleansing before colonoscopy, CT virtual colonoscopy, or bowel surgery. AKI secondary to acute phosphate nephropathy has been reported following the use of oral sodium phosphate preparations. Acute phosphate nephropathy is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/7218.html" rel="external">"Acute phosphate nephropathy"</a>.)</p><p class="headingAnchor" id="H4164478"><span class="h2">Ciprofloxacin</span><span class="headingEndMark"> — </span>The widely used fluoroquinolone antibiotic, <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a>, is known to cause AKI from acute interstitial nephritis [<a href="#rid51">51-53</a>]. Ciprofloxacin has also been reported to cause crystalluria in experimental animals [<a href="#rid54">54</a>] and both crystalluria [<a href="#rid55">55-57</a>] and crystal-induced AKI [<a href="#rid58">58-62</a>] in humans. In all reports, patients developed oliguric AKI within two days to two weeks of ingestion of oral ciprofloxacin. All case reports except one described patients who were ≥70 years of age, and two described patients who were on angiotensin-converting enzyme (ACE) inhibitors [<a href="#rid62">62</a>]. Urinalysis revealed crystals of varying shapes, which were composed of ciprofloxacin salt  (<a class="graphic graphic_picture graphicRef50067" href="/d/graphic/50067.html" rel="external">picture 4</a>).</p><p><a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">Ciprofloxacin</a> crystals typically precipitate in an alkaline pH [<a href="#rid55">55,63</a>]. However, crystals have been described in association with acidic urine pH in several case reports [<a href="#rid58">58,61</a>]. Ciprofloxacin crystals have been shown to display a wide array of appearances, including needles, sheaves, stars, fans, butterflies, and other unusual shapes. All crystals have had a lamellar structure, with sizes ranging from 30 x 5 microm to 360 x 237 microm, and are strongly birefringent under polarizing light [<a href="#rid64">64</a>]. Histology obtained by kidney biopsy in three patients revealed needle-shaped birefringent crystals within the tubules  (<a class="graphic graphic_picture graphicRef62878" href="/d/graphic/62878.html" rel="external">picture 5</a>) without evidence of acute or chronic interstitial nephritis [<a href="#rid61">61,62</a>]. In all patients, kidney function returned to baseline upon withdrawal of ciprofloxacin.</p><p>Risk factors for AKI include impaired kidney function, volume depletion, and a urine pH &gt;6 (although acidic urine pH does not preclude a diagnosis of ciprofloxacin-induced crystal deposition). To prevent <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> crystal-induced AKI, ciprofloxacin should be dose adjusted for level of glomerular filtration rate (GFR), the patient should be volume replete, and alkalinization of the urine should be avoided [<a href="#rid65">65</a>].</p><p class="headingAnchor" id="H35792890"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110752.html" rel="external">"Society guideline links: Acute kidney injury in adults"</a>.)</p><p class="headingAnchor" id="H4164485"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – Acute kidney injury (AKI) due to intratubular crystal precipitation is observed in association with many medications. Patients are generally asymptomatic, although occasionally present with flank pain. Urinalysis may show hematuria, pyuria, and crystals with a characteristic morphology. (See <a class="local">'Introduction'</a> above and <a class="local">'Clinical presentation and diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention of AKI</strong> – The maintenance of optimal volume status and correction of volume depletion is critical in the prevention of crystal-induced AKI from all causes. The alkalinization of urine may help prevent crystal-induced AKI secondary to <a class="drug drug_general" data-topicid="9960" href="/d/drug information/9960.html" rel="external">sulfadiazine</a> antibiotics and <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>. We suggest the following approach for patients who are receiving specific agents:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Acyclovir</strong> – Among patients who are receiving intravenous (IV) <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a>, we suggest the administration of IV isotonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> at a rate of 125 mL/hour, starting at least one hour prior to the administration of acyclovir and continuing for six hours after the acyclovir infusion is finished (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Acyclovir'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Sulfonamide antibiotics</strong> – Among patients who are receiving high-dose IV sulfonamide antibiotics and develop crystalluria, we suggest the administration of IV <a class="drug drug_general" data-topicid="9928" href="/d/drug information/9928.html" rel="external">sodium bicarbonate</a> to prevent AKI (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Sulfonamide antibiotics'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Methotrexate</strong> – Among patients who are receiving IV <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, we recommend the administration of IV <a class="drug drug_general" data-topicid="9928" href="/d/drug information/9928.html" rel="external">sodium bicarbonate</a> to prevent AKI (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Methotrexate'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of established AKI</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Optimizing volume status</strong> – The maintenance of optimal volume status and correction of volume depletion is critical in the treatment of established AKI. Among all patients with established crystal-induced AKI from any cause, we recommend the correction of volume depletion with IV fluid (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). In the absence of an indication for IV bicarbonate, such as for the treatment of sulfonamide- or methotrexate-induced AKI, the preferred IV fluid is usually isotonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a>. (See <a class="local">'Overview of treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Loop diuretics</strong> – Although efficacy has not been shown in this setting, the use of loop diuretics may be effective in clearing obstructing casts in crystal-induced AKI. Among all volume-replete patients with established crystal-induced AKI from any cause, we suggest administration of a loop diuretic (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Fluid loss induced by the diuretic must be replaced to prevent volume depletion and a late slowing of flow within the tubules. (See <a class="local">'Risk factors'</a> above and <a class="local">'Overview of treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>AKI associated with sulfonamide or </strong><strong>methotrexate</strong> – Crystals from sulfonamide antibiotics and <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> are more likely to form in acidic urine. Alkalinization of urine may provide benefit in established AKI from sulfonamide antibiotics or methotrexate. <a class="drug drug_general" data-topicid="9548" href="/d/drug information/9548.html" rel="external">Leucovorin</a> rescue is used in patients with methotrexate-associated AKI and elevated plasma methotrexate concentrations. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Among patients with established sulfonamide-associated AKI who are not oliguric and do not have hypocalcemia or metabolic alkalosis or an indication for acute hemodialysis, we suggest the administration of IV bicarbonate with a target urine pH of &gt;7.15 (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Sulfonamide antibiotics'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Among patients with established methotrexate-associated AKI who are not oliguric and do not have hypocalcemia or metabolic alkalosis or an indication for acute hemodialysis, we suggest the administration of IV bicarbonate with a target urine pH of &gt;7 (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Methotrexate'</a> above.)</p><p></p><p class="bulletIndent3">Methotrexate-induced AKI often results in an elevated plasma <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> concentration, which may increase the systemic toxicity of methotrexate. <a class="drug drug_general" data-topicid="9548" href="/d/drug information/9548.html" rel="external">Leucovorin</a> rescue, with or without thymidine or <a class="drug drug_general" data-topicid="9048" href="/d/drug information/9048.html" rel="external">glucarpidase</a>, may be effective in this setting. (See <a class="local">'Methotrexate'</a> above and  <a class="medical medical_review" href="/d/html/7509.html" rel="external">"Major side effects of low-dose methotrexate"</a> and  <a class="medical medical_review" href="/d/html/1155.html" rel="external">"Therapeutic use and toxicity of high-dose methotrexate", section on 'Glucarpidase (carboxypeptidase G2)'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Avoiding urine acidification</strong> – Crystals from protease inhibitors such as <a class="drug drug_general" data-topicid="9353" href="/d/drug information/9353.html" rel="external">atazanavir</a> are more likely to form in alkaline urine. However, it is difficult and potentially dangerous to acidify the urine among patients with established AKI. We recommend <strong>not </strong>acidifying the urine for the treatment of crystal-induced AKI from any cause (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>).</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Perazella MA. Crystal-induced acute renal failure. Am J Med 1999; 106:459.</a></li><li><a class="nounderline abstract_t">Teichman JM. Clinical practice. Acute renal colic from ureteral calculus. N Engl J Med 2004; 350:684.</a></li><li><a class="nounderline abstract_t">Hentzien M, Lambert D, Limelette A, et al. Macroscopic amoxicillin crystalluria. Lancet 2015; 385:2296.</a></li><li><a class="nounderline abstract_t">Sawyer MH, Webb DE, Balow JE, Straus SE. Acyclovir-induced renal failure. Clinical course and histology. Am J Med 1988; 84:1067.</a></li><li><a class="nounderline abstract_t">Berns JS, Cohen RM, Stumacher RJ, Rudnick MR. Renal aspects of therapy for human immunodeficiency virus and associated opportunistic infections. J Am Soc Nephrol 1991; 1:1061.</a></li><li><a class="nounderline abstract_t">Brigden D, Rosling AE, Woods NC. Renal function after acyclovir intravenous injection. Am J Med 1982; 73:182.</a></li><li><a class="nounderline abstract_t">Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Studies of ocular complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. Arch Intern Med 1995; 155:65.</a></li><li><a class="nounderline abstract_t">Inaba I, Kondo Y, Iwasaki S, et al. Risk Evaluation for Acute Kidney Injury Induced by the Concomitant Use of Valacyclovir, Analgesics, and Renin-Angiotensin System Inhibitors: The Detection of Signals of Drug-Drug Interactions. Front Pharmacol 2019; 10:874.</a></li><li><a class="nounderline abstract_t">Roberts DM, Smith MW, McMullan BJ, et al. Acute kidney injury due to crystalluria following acute valacyclovir overdose. Kidney Int 2011; 79:574.</a></li><li><a class="nounderline abstract_t">Krieble BF, Rudy DW, Glick MR, Clayman MD. Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis. Am J Med Sci 1993; 305:36.</a></li><li><a class="nounderline abstract_t">Obada EN, Level G, Mathieu P, et al. [Acute renal failure following a treatment with acyclovir]. Nephrol Ther 2010; 6:125.</a></li><li><a class="nounderline abstract_t">Giustina A, Romanelli G, Cimino A, Brunori G. Low-dose acyclovir and acute renal failure. Ann Intern Med 1988; 108:312.</a></li><li><a class="nounderline abstract_t">Eck P, Silver SM, Clark EC. Acute renal failure and coma after a high dose of oral acyclovir. N Engl J Med 1991; 325:1178.</a></li><li><a class="nounderline abstract_t">Spiegal DM, Lau K. Acute renal failure and coma secondary to acyclovir therapy. JAMA 1986; 255:1882.</a></li><li><a class="nounderline abstract_t">Cohen SM, Minkove JA, Zebley JW 3rd, Mulholland JH. Severe but reversible neurotoxicity from acyclovir. Ann Intern Med 1984; 100:920.</a></li><li><a class="nounderline abstract_t">Simon DI, Brosius FC 3rd, Rothstein DM. Sulfadiazine crystalluria revisited. The treatment of Toxoplasma encephalitis in patients with acquired immunodeficiency syndrome. Arch Intern Med 1990; 150:2379.</a></li><li><a class="nounderline abstract_t">Carbone LG, Bendixen B, Appel GB. Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome. Am J Kidney Dis 1988; 12:72.</a></li><li><a class="nounderline abstract_t">Hein R, Brunkhorst R, Thon WF, et al. Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases. Clin Nephrol 1993; 39:254.</a></li><li><a class="nounderline abstract_t">Sasson JP, Dratch PL, Shortsleeve MJ. Renal US findings in sulfadiazine-induced crystalluria. Radiology 1992; 185:739.</a></li><li><a class="nounderline abstract_t">Melli G, Chaudhry V, Cornblath DR. Rhabdomyolysis: an evaluation of 475 hospitalized patients. Medicine (Baltimore) 2005; 84:377.</a></li><li class="breakAll">Garrick, MB, Mayer, et al. Acute renal failure associated with cancer treatment. In: Acute Renal Failure, 2nd ed, Brenner, BM, Lazarus, JM (Eds), Churchill Livingstone, New York 1988. p.636.</li><li><a class="nounderline abstract_t">Pitman SW, Frei E 3rd. Weekly methotrexate-calcium leucovorin rescue: effect of alkalinization on nephrotoxicity; pharmacokinetics in the CNS; and use in CNS non-Hodgkin's lymphoma. Cancer Treat Rep 1977; 61:695.</a></li><li><a class="nounderline abstract_t">Abelson HT, Fosburg MT, Beardsley GP, et al. Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine. J Clin Oncol 1983; 1:208.</a></li><li><a class="nounderline abstract_t">Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist 2006; 11:694.</a></li><li><a class="nounderline abstract_t">Widemann BC, Balis FM, Kempf-Bielack B, et al. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma. Cancer 2004; 100:2222.</a></li><li><a class="nounderline abstract_t">Amitai I, Rozovski U, El-Saleh R, et al. Risk factors for high-dose methotrexate associated acute kidney injury in patients with hematological malignancies. Hematol Oncol 2020; 38:584.</a></li><li><a class="nounderline abstract_t">Barreto JN, Kashani KB, Mara KC, et al. A Prospective Evaluation of Novel Renal Biomarkers in Patients With Lymphoma Receiving High-Dose Methotrexate. Kidney Int Rep 2022; 7:1690.</a></li><li><a class="nounderline abstract_t">Krause AS, Weihrauch MR, Bode U, et al. Carboxypeptidase-G2 rescue in cancer patients with delayed methotrexate elimination after high-dose methotrexate therapy. Leuk Lymphoma 2002; 43:2139.</a></li><li><a class="nounderline abstract_t">Widemann BC, Balis FM, Murphy RF, et al. Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction. J Clin Oncol 1997; 15:2125.</a></li><li><a class="nounderline abstract_t">Buchen S, Ngampolo D, Melton RG, et al. Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure. Br J Cancer 2005; 92:480.</a></li><li class="breakAll">VORAXAZE (glucarpidase). For Injection, for intravenous use. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125327lbl.pdf?et_cid=28599956&amp;et_rid=463638624&amp;linkid=http%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2012%2f125327lbl.pdf (Accessed on January 18, 2012).</li><li><a class="nounderline abstract_t">Garella S. Extracorporeal techniques in the treatment of exogenous intoxications. Kidney Int 1988; 33:735.</a></li><li><a class="nounderline abstract_t">Wall SM, Johansen MJ, Molony DA, et al. Effective clearance of methotrexate using high-flux hemodialysis membranes. Am J Kidney Dis 1996; 28:846.</a></li><li><a class="nounderline abstract_t">Pasko DA, Grio M, Thomas S, et al. Methotrexate transmembrane clearance during albumin based continuous veno-venous hemodialysis. Blood Purif 2005; 23:165.</a></li><li><a class="nounderline abstract_t">Brewster UC, Perazella MA. Acute interstitial nephritis associated with atazanavir, a new protease inhibitor. Am J Kidney Dis 2004; 44:e81.</a></li><li><a class="nounderline abstract_t">Couzigou C, Daudon M, Meynard JL, et al. Urolithiasis in HIV-positive patients treated with atazanavir. Clin Infect Dis 2007; 45:e105.</a></li><li><a class="nounderline abstract_t">Chang HR, Pella PM. Atazanavir urolithiasis. N Engl J Med 2006; 355:2158.</a></li><li><a class="nounderline abstract_t">Izzedine H, M'rad MB, Bardier A, et al. Atazanavir crystal nephropathy. AIDS 2007; 21:2357.</a></li><li><a class="nounderline abstract_t">Nadler RB, Rubenstein JN, Eggener SE, et al. The etiology of urolithiasis in HIV infected patients. J Urol 2003; 169:475.</a></li><li><a class="nounderline abstract_t">Chan-Tack KM, Truffa MM, Struble KA, Birnkrant DB. Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Adverse Event Reporting System. AIDS 2007; 21:1215.</a></li><li><a class="nounderline abstract_t">Soto K, Campos P, Manso R, et al. Severe Acute Kidney Injury and Double Tubulopathy Due to Dual Toxicity Caused by Combination Antiretroviral Therapy. Kidney Int Rep 2019; 4:494.</a></li><li><a class="nounderline abstract_t">McLaughlin MM, Guerrero AJ, Merker A. Renal effects of non-tenofovir antiretroviral therapy in patients living with HIV. Drugs Context 2018; 7:212519.</a></li><li><a class="nounderline abstract_t">Swartz RD, Wesley JR, Somermeyer MG, Lau K. Hyperoxaluria and renal insufficiency due to ascorbic acid administration during total parenteral nutrition. Ann Intern Med 1984; 100:530.</a></li><li><a class="nounderline abstract_t">Nakamoto Y, Motohashi S, Kasahara H, Numazawa K. Irreversible tubulointerstitial nephropathy associated with prolonged, massive intake of vitamin C. Nephrol Dial Transplant 1998; 13:754.</a></li><li><a class="nounderline abstract_t">Bnaya A, Abu-Amer N, Beckerman P, et al. Acute Kidney Injury and Hair-Straightening Products: A Case Series. Am J Kidney Dis 2023; 82:43.</a></li><li><a class="nounderline abstract_t">Courtney AE, O'Rourke DM, Maxwell AP. Rapidly progressive renal failure associated with successful pharmacotherapy for obesity. Nephrol Dial Transplant 2007; 22:621.</a></li><li><a class="nounderline abstract_t">Singh A, Sarkar SR, Gaber LW, Perazella MA. Acute oxalate nephropathy associated with orlistat, a gastrointestinal lipase inhibitor. Am J Kidney Dis 2007; 49:153.</a></li><li><a class="nounderline abstract_t">Weir MA, Beyea MM, Gomes T, et al. Orlistat and acute kidney injury: an analysis of 953 patients. Arch Intern Med 2011; 171:703.</a></li><li><a class="nounderline abstract_t">Demoulin N, Aydin S, Gillion V, et al. Pathophysiology and Management of Hyperoxaluria and Oxalate Nephropathy: A Review. Am J Kidney Dis 2022; 79:717.</a></li><li><a class="nounderline abstract_t">Llanos M, Kwon A, Herlitz L, et al. The Clinical and Pathological Characteristics of Patients with Oxalate Nephropathy. Kidney360 2024; 5:65.</a></li><li><a class="nounderline abstract_t">Hootkins R, Fenves AZ, Stephens MK. Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature. Clin Nephrol 1989; 32:75.</a></li><li><a class="nounderline abstract_t">Connor JP, Curry JM, Selby TL, Perlmutter AD. Acute renal failure secondary to ciprofloxacin use. J Urol 1994; 151:975.</a></li><li><a class="nounderline abstract_t">Markowitz GS, Perazella MA. Drug-induced renal failure: a focus on tubulointerstitial disease. Clin Chim Acta 2005; 351:31.</a></li><li><a class="nounderline abstract_t">Ball P. Ciprofloxacin: an overview of adverse experiences. J Antimicrob Chemother 1986; 18 Suppl D:187.</a></li><li><a class="nounderline abstract_t">Thorsteinsson SB, Bergan T, Oddsdottir S, et al. Crystalluria and ciprofloxacin, influence of urinary pH and hydration. Chemotherapy 1986; 32:408.</a></li><li><a class="nounderline abstract_t">Thorsteinsson SB, Bergan T, Rohwedder R. Tolerance of intravenously administered ciprofloxacin. Chemotherapy 1988; 34:256.</a></li><li><a class="nounderline abstract_t">Ball P, Tillotson G. Tolerability of fluoroquinolone antibiotics. Past, present and future. Drug Saf 1995; 13:343.</a></li><li><a class="nounderline abstract_t">Chopra N, Fine PL, Price B, Atlas I. Bilateral hydronephrosis from ciprofloxacin induced crystalluria and stone formation. J Urol 2000; 164:438.</a></li><li><a class="nounderline abstract_t">Dharnidharka VR, Nadeau K, Cannon CL, et al. Ciprofloxacin overdose: acute renal failure with prominent apoptotic changes. Am J Kidney Dis 1998; 31:710.</a></li><li><a class="nounderline abstract_t">Sedlacek M, Suriawinata AA, Schoolwerth A, Remillard BD. Ciprofloxacin crystal nephropathy--a 'new' cause of acute renal failure. Nephrol Dial Transplant 2006; 21:2339.</a></li><li><a class="nounderline abstract_t">Stratta P, Lazzarich E, Canavese C, et al. Ciprofloxacin crystal nephropathy. Am J Kidney Dis 2007; 50:330.</a></li><li><a class="nounderline abstract_t">Montagnac R, Briat C, Schillinger F, et al. [Fluoroquinolone induced acute renal failure. General review about a case report with crystalluria due to ciprofloxacin]. Nephrol Ther 2005; 1:44.</a></li><li><a class="nounderline abstract_t">Schluter G. Ciprofloxacin: toxicologic evaluation of additional safety data. Am J Med 1989; 87:37S.</a></li><li><a class="nounderline abstract_t">Fogazzi GB, Garigali G, Brambilla C, Daudon M. Ciprofloxacin crystalluria. Nephrol Dial Transplant 2006; 21:2982.</a></li><li><a class="nounderline abstract_t">Christ W, Lehnert T, Ulbrich B. Specific toxicologic aspects of the quinolones. Rev Infect Dis 1988; 10 Suppl 1:S141.</a></li></ol></div><div id="topicVersionRevision">Topic 7229 Version 32.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10225250" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Crystal-induced acute renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14960744" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Clinical practice. Acute renal colic from ureteral calculus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25680270" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Macroscopic amoxicillin crystalluria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3376977" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Acyclovir-induced renal failure. Clinical course and histology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1912406" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Renal aspects of therapy for human immunodeficiency virus and associated opportunistic infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6285711" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Renal function after acyclovir intravenous injection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7802522" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Studies of ocular complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31440161" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Risk Evaluation for Acute Kidney Injury Induced by the Concomitant Use of Valacyclovir, Analgesics, and Renin-Angiotensin System Inhibitors: The Detection of Signals of Drug-Drug Interactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21321560" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Acute kidney injury due to crystalluria following acute valacyclovir overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8416680" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20117065" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : [Acute renal failure following a treatment with acyclovir].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3341668" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Low-dose acyclovir and acute renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1891032" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Acute renal failure and coma after a high dose of oral acyclovir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3951115" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Acute renal failure and coma secondary to acyclovir therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6721312" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Severe but reversible neurotoxicity from acyclovir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2241449" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Sulfadiazine crystalluria revisited. The treatment of Toxoplasma encephalitis in patients with acquired immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3389358" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8513601" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1438755" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Renal US findings in sulfadiazine-induced crystalluria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16267412" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Rhabdomyolysis: an evaluation of 475 hospitalized patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16267412" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Rhabdomyolysis: an evaluation of 475 hospitalized patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18282" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Weekly methotrexate-calcium leucovorin rescue: effect of alkalinization on nephrotoxicity; pharmacokinetics in the CNS; and use in CNS non-Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6607976" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16794248" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Understanding and managing methotrexate nephrotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15139068" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32506594" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Risk factors for high-dose methotrexate associated acute kidney injury in patients with hematological malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35812294" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : A Prospective Evaluation of Novel Renal Biomarkers in Patients With Lymphoma Receiving High-Dose Methotrexate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12533039" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Carboxypeptidase-G2 rescue in cancer patients with delayed methotrexate elimination after high-dose methotrexate therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9164227" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15668713" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15668713" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3285069" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Extracorporeal techniques in the treatment of exogenous intoxications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8957036" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Effective clearance of methotrexate using high-flux hemodialysis membranes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Methotrexate transmembrane clearance during albumin based continuous veno-venous hemodialysis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15492941" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Acute interstitial nephritis associated with atazanavir, a new protease inhibitor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17879904" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Urolithiasis in HIV-positive patients treated with atazanavir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17108352" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Atazanavir urolithiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18090291" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Atazanavir crystal nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12544290" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The etiology of urolithiasis in HIV infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17502736" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Adverse Event Reporting System.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30899878" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Severe Acute Kidney Injury and Double Tubulopathy Due to Dual Toxicity Caused by Combination Antiretroviral Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29623097" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Renal effects of non-tenofovir antiretroviral therapy in patients living with HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6422817" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Hyperoxaluria and renal insufficiency due to ascorbic acid administration during total parenteral nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9550660" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Irreversible tubulointerstitial nephropathy associated with prolonged, massive intake of vitamin C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36610611" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Acute Kidney Injury and Hair-Straightening Products: A Case Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17121780" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Rapidly progressive renal failure associated with successful pharmacotherapy for obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17185156" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Acute oxalate nephropathy associated with orlistat, a gastrointestinal lipase inhibitor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21482850" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Orlistat and acute kidney injury: an analysis of 953 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34508834" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Pathophysiology and Management of Hyperoxaluria and Oxalate Nephropathy: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38095544" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The Clinical and Pathological Characteristics of Patients with Oxalate Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2670382" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8126841" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Acute renal failure secondary to ciprofloxacin use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15563870" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Drug-induced renal failure: a focus on tubulointerstitial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3542945" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Ciprofloxacin: an overview of adverse experiences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3019613" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Crystalluria and ciprofloxacin, influence of urinary pH and hydration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3416662" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Tolerance of intravenously administered ciprofloxacin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8652079" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Tolerability of fluoroquinolone antibiotics. Past, present and future.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10893604" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Bilateral hydronephrosis from ciprofloxacin induced crystalluria and stone formation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9531191" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Ciprofloxacin overdose: acute renal failure with prominent apoptotic changes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16611679" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Ciprofloxacin crystal nephropathy--a 'new' cause of acute renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17660035" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Ciprofloxacin crystal nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16895667" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : [Fluoroquinolone induced acute renal failure. General review about a case report with crystalluria due to ciprofloxacin].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2589381" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Ciprofloxacin: toxicologic evaluation of additional safety data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16837513" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Ciprofloxacin crystalluria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3279489" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Specific toxicologic aspects of the quinolones.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
